跳至主要内容
临床试验/NCT06084546
NCT06084546尚未招募不适用

Evaluation of the Adhesive Strength of an Improved Skin Adhesive Hydrogel Formulation Designated KM40C Incorporated in the Geko™ X-W3 Neuromuscular Electrical Stimulator (NMES) Device in Patients With Lower Limb Ulcers

Firstkind Ltd4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2023年12月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
Firstkind Ltd
入组人数
30
试验地点
4
主要终点
Efficacy of the Skin Adhesive Strength of Hydrogel KM40C Compared to That of Hydrogel KM40A

研究概览

简要总结

Hydrogel KM40C is an electrically conductive skin adhesive incorporated in the self-adhesive, geko™ XW-3 neuromuscular electrical stimulation (NMES) device. KM40C has been formulated to adhere to the skin giving good electrical contact for the electrodes, be easy to remove without damaging the skin and be non-irritant. KM40C has been tested for safety in humans, however the skin adhesive performance of this improved hydrogel formulation has not been tested on patients receiving geko™ NMES treatment as an adjunct to standard care for wound management.

The objective of this trial is to evaluate the skin adhesive performance of hydrogel KM40C during clinical use of the geko™ XW-3 NMES device to determine whether skin adhesion is at least equivalent if not superior to the adhesive hydrogel KM40A incorporated in the self-adhesive geko™ W3 device which is currently in use clinically. Both devices are indicated for use to promote wound healing, the geko™ W3 NMES device is UKCA and CE marked whereas the geko™ X-W3 is UK CA marked only.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who have a lower limb ulcer following evaluation by a Tissue Viability Nurse Specialist
  • Intact healthy skin at the site of geko™ device application.
  • Willing and able to give written informed consent
  • Identified to receive geko™ treatment as an adjunct to standard care for wound management.

排除标准

  • Pregnancy or breast feeding
  • Use of any other neuro-modulation device.
  • Use of a cardiac pacemaker
  • Current use of TENS in the pelvic region, back or legs
  • Contraindication to geko ™ NMES treatment
  • No response to geko ™ NMES i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting.
  • Participation in any other clinical trial that may interfere with the outcome of either trial.

结局指标

主要结局

Efficacy of the Skin Adhesive Strength of Hydrogel KM40C Compared to That of Hydrogel KM40A

时间窗: 28 days

Self reported - how well did the geko™ device stick to the patients leg? Scale 1-5, Lowest score indicates best adhesion.

次要结局

  • Incidence of Adverse Events(28 days)

研究者

发起方
Firstkind Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验